Abstract 248P
Background
Over the past decade, a growing body of literature has elucidated the involvement of zinc homeostasis in tumor growth and progression. Herein, we present a bioinformatics-based study to evaluate the prognostic potential of zinc homeostasis-related genes in ccRCC.
Methods
The Human Genome Atlas Program (TCGA) was accessed to retrieve level 3 omics data and the corresponding clinicopathological variables. Differential expression of zinc homeostasis-related genes were considered statistically significant with a |Log2(fold change)| ≥ 1.5 and a P-value ≤ .01. The prognostic potential of selected genes was assessed using multivariate Cox logistic regression analysis. LinkedOmics was used to functionally annotate significantly co-expressed genes using KEGG terminology. Enrichment of the hallmarks of cancer gene sets was tested using gene set enrichment analysis (GSEA). Tumor immune microenvironment was explored using TIMER 2.0.
Results
A total of five significant differentially expressed genes were detected, including MT1G, SLC30A2, MT1F, SLC39A1, and MT1H. The latter being the only gene with a significant prognostic profile. High MT1H expression is associated with shortened overall survival (HR: 1.534, 95% CI: 1.140-2.064, P < .0048). Multivariate Cox logistic regression identified MT1H as an independent prognostic biomarker in ccRCC (HR: 1.392, 95% CI: 1.016-1.907, P < .04). MT1H co-expressed genes annotation highlighted the involvement of mineral absorption, ribosome, oxidative phosphorylation, and proteasome pathways. GSEA illustrated several alternations in epithelial-mesenchymal transition, inflammatory response,coagulation, complement, IL-6/JAK/STAT3 signaling, glycolysis, KRAS signaling, hypoxia, E2F targets, estrogen response, INF-γ signaling, and apoptosis. No clear trends or patterns were observed in tumor immune microenvironment in response to MT1H upregulation.
Conclusions
MT1H has been identified as a potential prognostic biomarker in ccRCC. Further experimental studies are needed to confirm the observed findings and to detect the exact molecular modulators involved.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract